Congo's Ebola Outbreak Is Spreading Faster Than Any Before — and There's No Approved Vaccine

On August 18, 2026, the World Health Organization warned that the Ebola outbreak in the Democratic Republic of the Congo remains a global health emergency, with confirmed infections surpassing 5,000 and the death toll exceeding 2,320 (Al Jazeera). WHO Director-General Tedros Adhanom Ghebreyesus said the outbreak is spreading at an unprecedented speed and is far from under control.

This is the seventeenth Ebola outbreak recorded in the DRC and its deadliest, surpassing fatalities from the 2018–2020 outbreak. The virus responsible is the Bundibugyo ebolavirus species, for which no approved vaccine or treatment exists. That is a critical distinction from the Zaire ebolavirus species that drove earlier Central African epidemics, and for which a vaccine called rVSV-ZEBOV was deployed under compassionate-use protocols — meaning it was given to people before full approval because the situation was urgent.

The outbreak was officially declared on May 17, 2026, the same day WHO determined that the epidemic of Ebola disease caused by the Bundibugyo virus in the DRC and Uganda constituted a Public Health Emergency of International Concern, or PHEIC (WHO). A PHEIC is WHO's highest-level alert, meant to coordinate a global response. Genetic sequencing, however, indicates sustained human-to-human transmission began as early as February 2026, meaning the virus circulated undetected for roughly three months before formal declaration. The IHR Emergency Committee — a panel of experts that advises WHO under the International Health Regulations — convened its first meeting on the epidemic on May 22, 2026, issuing temporary recommendations to member states.

The trajectory has been steep. As of July 2, 2026, WHO reported 1,406 cases with an average of 38 new confirmed cases per day (WHO). By August 18, that figure had climbed past 5,000 — a more than threefold increase in roughly seven weeks.

Two factors complicate the response. First, the eastern DRC's security environment continues to deteriorate, limiting humanitarian access. Since the PHEIC declaration on May 17, WHO has documented 12 attacks on health care in the outbreak zone (WHO). On August 17, 2026, WHO published operational guidance titled "Protecting health care during the Bundibugyo virus disease response in the eastern Democratic Republic," providing practical considerations for integrating protection measures and maintaining continuity of essential health services (WHO).

Second, the absence of a licensed Bundibugyo vaccine has forced reliance on experimental candidates still in early clinical evaluation. The first volunteer received an experimental Bundibugyo-strain vaccine in the United Kingdom in July 2026. Hundreds of thousands of doses of an Oxford University-developed candidate have been manufactured in India as of August 2026, though no efficacy data from phase III trials — the large-scale studies that confirm whether a vaccine actually works — have been reported. The gap between manufacturing scale-up and clinical evidence creates a familiar tension for outbreak vaccinology: deploy under emergency protocols before confirming protection, or wait while transmission accelerates.

WHO's response strategy in the DRC has adapted to the region's logistical realities by recruiting motorbike riders as surveillance and response officers, leveraging their transport routes for contact tracing (the process of finding and monitoring everyone who has been near an infected person) and alert reporting. The cross-border dimension, with confirmed cases in both the DRC and Uganda, adds coordination complexity under the IHR framework.

The broader context here is the interplay between pathogen characteristics, health system fragility, and conflict. The Bundibugyo species, first identified in 2007 in Uganda's Bundibugyo District, has historically been associated with lower case-fatality ratios — the share of infected people who die — than Zaire ebolavirus, but unpredictable transmission dynamics. In a setting where armed group activity restricts access, where contact tracing depends on informal transport networks, and where the only available vaccine is unlicensed, the conventional pillars of Ebola containment — rapid isolation, contact tracing, ring vaccination (vaccinating the contacts of infected people and their contacts, forming a protective ring), and safe burial practices — are each operating under significant strain. The case-fatality ratio implied by the August 18 figures (approximately 46%) sits within the range observed in prior Bundibugyo outbreaks, but the absolute mortality is unprecedented for this species.

What to watch next is whether the Oxford candidate progresses rapidly enough through clinical evaluation to support an emergency-use authorization, and whether the 12 documented attacks on health care since the PHEIC declaration signal a deteriorating trend or a stable baseline of insecurity. The speed Tedros describes leaves little margin for either variable to move in the wrong direction.